Israel Englander’s BridgeBio Pharma BBIO Stock Holding History

Israel Englander’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$13.6M	Buy	+182,200	New	+$12.8M	﹤0.01%	1994
2025 Q4	–	Sell	-50,000	Closed	-$2.6M	–	6012
2025 Q3	$2.6M	Buy	50,000 +26,300	+111%	+$1.28M	﹤0.01%	3806
2025 Q2	$1.02M	Buy	23,700 +10,000	+73%	+$364K	﹤0.01%	4387
2025 Q1	$474K	Buy	+13,700	New	+$462K	﹤0.01%	4849
2024 Q2	–	Sell	-15,700	Closed	-$485K	–	5879
2024 Q1	$485K	Buy	+15,700	New	+$534K	﹤0.01%	4841
2023 Q3	–	Sell	-302,700	Closed	-$5.21M	–	6117
2023 Q2	$5.21M	Buy	302,700 +199,900	+194%	+$3.01M	﹤0.01%	2641
2023 Q1	$1.7M	Buy	+102,800	New	+$1.2M	﹤0.01%	3591
2022 Q2	–	Sell	-100,000	Closed	-$1.01M	–	6966
2022 Q1	$1.01M	Buy	100,000 +40,000	+67%	+$411K	﹤0.01%	4499
2021 Q4	$1M	Buy	+60,000	New	+$2.54M	﹤0.01%	4406
2021 Q1	–	Sell	-8,000	Closed	-$569K	–	5903
2020 Q4	$569K	Buy	+8,000	New	+$386K	﹤0.01%	4095

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Israel Englander's BBIO Position: Q2 2026 in Review

Israel Englander reduced its BridgeBio Pharma (BBIO) stake by 23% in Q2 2026, selling an estimated $10.2M and leaving 487,594 shares worth $36.3M. The position accounts for 0.01% of the portfolio, ranked #1119.

Israel Englander first reported a position in BBIO in Q2 2019 and has held it in 26 quarters since. The position peaked at $47M in Q1 2026. 472 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Israel Englander held 487,594 shares of BridgeBio Pharma worth $36.3M as of Q2 2026.
Israel Englander sold 145,689 BridgeBio Pharma shares in Q2 2026, an estimated $10.2M.
BridgeBio Pharma made up 0.01% of Israel Englander's portfolio in Q2 2026, its #1119 holding.
Israel Englander first reported a position in BridgeBio Pharma in Q2 2019 and has held it in 26 quarters since.
Israel Englander's BridgeBio Pharma position peaked at $47M in Q1 2026.
472 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.